Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas

Authors: Keith M Skubitz, Amy PN Skubitz, Wayne W Xu, Xianghua Luo, Pauline Lagarde, Jean-Michel Coindre, Frédéric Chibon

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The biologic heterogeneity of soft tissue sarcomas (STS), even within histological subtypes, complicates treatment. In earlier studies, gene expression patterns that distinguish two subsets of clear cell renal carcinoma (RCC), serous ovarian carcinoma (OVCA), and aggressive fibromatosis (AF) were used to separate 73 STS into two or four groups with different probabilities of developing metastatic disease (PrMet). This study was designed to confirm our earlier observations in a larger independent data set.

Methods

We utilized these gene sets, hierarchical clustering (HC), and Kaplan-Meier analysis, to examine 309 STS, using Affymetrix chip expression profiling.

Results

HC using the combined AF-, RCC-, and OVCA-gene sets identified subsets of the STS samples. Analysis revealed differences in PrMet between the clusters defined by the first branch point of the clustering dendrogram (p = 0.048), and also among the four different clusters defined by the second branch points (p < 0.0001). Analysis also revealed differences in PrMet between the leiomyosarcomas (LMS), dedifferentiated liposarcomas (LipoD), and undifferentiated pleomorphic sarcomas (UPS) (p = 0.0004). HC of both the LipoD and UPS sample sets divided the samples into two groups with different PrMet (p = 0.0128, and 0.0002, respectively). HC of the UPS samples also showed four groups with different PrMet (p = 0.0007). HC found no subgroups of the LMS samples.

Conclusions

These data confirm our earlier studies, and suggest that this approach may allow the identification of more than two subsets of STS, each with distinct clinical behavior, and may be useful to stratify STS in clinical trials and in patient management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Helias-Rodzewicz Z, Pedeutour F, Coindre JM, Terrier P, Aurias A: Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer. 2009, 48 (11): 943-952.CrossRefPubMed Helias-Rodzewicz Z, Pedeutour F, Coindre JM, Terrier P, Aurias A: Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer. 2009, 48 (11): 943-952.CrossRefPubMed
2.
go back to reference Ladanyi M, Bridge JA: Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol. 2000, 31 (5): 532-538.CrossRefPubMed Ladanyi M, Bridge JA: Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol. 2000, 31 (5): 532-538.CrossRefPubMed
3.
5.
6.
go back to reference Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M: Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001, 19 (12): 3045-3050.PubMed Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M: Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001, 19 (12): 3045-3050.PubMed
7.
go back to reference Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K, Yoshida T, Toyama Y, Ichikawa H, Hasegawa T: Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007, 20 (7): 749-759.CrossRefPubMed Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K, Yoshida T, Toyama Y, Ichikawa H, Hasegawa T: Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007, 20 (7): 749-759.CrossRefPubMed
8.
go back to reference Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M: Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002, 359 (9314): 1301-1307.CrossRefPubMed Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M: Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002, 359 (9314): 1301-1307.CrossRefPubMed
9.
go back to reference Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C: Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003, 163 (2): 691-700.PubMedCentralCrossRefPubMed Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C: Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003, 163 (2): 691-700.PubMedCentralCrossRefPubMed
10.
go back to reference Skubitz KM, Skubitz AP: Characterization of sarcomas by means of gene expression. J Lab Clin Med. 2004, 144 (2): 78-91.CrossRefPubMed Skubitz KM, Skubitz AP: Characterization of sarcomas by means of gene expression. J Lab Clin Med. 2004, 144 (2): 78-91.CrossRefPubMed
11.
go back to reference Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrior P, Bonvalot S, LeCesne A, Vince-Panchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010, 16 (7): 781-787.CrossRefPubMed Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrior P, Bonvalot S, LeCesne A, Vince-Panchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010, 16 (7): 781-787.CrossRefPubMed
12.
go back to reference Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007, 8: 73-PubMedCentralCrossRefPubMed Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007, 8: 73-PubMedCentralCrossRefPubMed
13.
go back to reference Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP: Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest. 2005, 23 (2): 105-118.CrossRefPubMed Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP: Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest. 2005, 23 (2): 105-118.CrossRefPubMed
14.
go back to reference Skubitz KM, Francis P, Skubitz AP, Luo X, Nilbert M: Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas. Cancer. 2012, 118 (17): 4235-4243.CrossRefPubMed Skubitz KM, Francis P, Skubitz AP, Luo X, Nilbert M: Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas. Cancer. 2012, 118 (17): 4235-4243.CrossRefPubMed
15.
go back to reference Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med. 2008, 6: 23-PubMedCentralCrossRefPubMed Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med. 2008, 6: 23-PubMedCentralCrossRefPubMed
16.
go back to reference Skubitz KM, Skubitz AP: Differential gene expression in leiomyosarcoma. Cancer. 2003, 98 (5): 1029-1038.CrossRefPubMed Skubitz KM, Skubitz AP: Differential gene expression in leiomyosarcoma. Cancer. 2003, 98 (5): 1029-1038.CrossRefPubMed
17.
go back to reference Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P: A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res. 2009, 15 (16): 5191-5198.CrossRefPubMed Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P: A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res. 2009, 15 (16): 5191-5198.CrossRefPubMed
18.
go back to reference Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, Sciot R, Wozniak A, Schoffski P, Terrier P, Neuville A, Coindre JM, Italiano A, Orbach D, Debiec-Rychter M, Chibon F: Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013, 31 (5): 608-615.CrossRefPubMed Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, Sciot R, Wozniak A, Schoffski P, Terrier P, Neuville A, Coindre JM, Italiano A, Orbach D, Debiec-Rychter M, Chibon F: Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013, 31 (5): 608-615.CrossRefPubMed
19.
go back to reference Skubitz AP, Pambuccian SE, Argenta PA, Skubitz KM: Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res. 2006, 148 (5): 223-248.CrossRefPubMed Skubitz AP, Pambuccian SE, Argenta PA, Skubitz KM: Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res. 2006, 148 (5): 223-248.CrossRefPubMed
20.
go back to reference Skubitz KM, Skubitz AP: Differential gene expression in renal-cell cancer. J Lab Clin Med. 2002, 140 (1): 52-64.CrossRefPubMed Skubitz KM, Skubitz AP: Differential gene expression in renal-cell cancer. J Lab Clin Med. 2002, 140 (1): 52-64.CrossRefPubMed
21.
go back to reference Skubitz KM, Skubitz AP: Gene expression in aggressive fibromatosis. J Lab Clin Med. 2004, 143 (2): 89-98.CrossRefPubMed Skubitz KM, Skubitz AP: Gene expression in aggressive fibromatosis. J Lab Clin Med. 2004, 143 (2): 89-98.CrossRefPubMed
22.
go back to reference Skubitz KM, Zimmermann W, Kammerer R, Pambuccian S, Skubitz AP: Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006, 147 (5): 250-267.CrossRefPubMed Skubitz KM, Zimmermann W, Kammerer R, Pambuccian S, Skubitz AP: Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006, 147 (5): 250-267.CrossRefPubMed
23.
go back to reference Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS, Han ZG: Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest. 2010, 120 (1): 223-241.PubMedCentralCrossRefPubMed Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS, Han ZG: Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest. 2010, 120 (1): 223-241.PubMedCentralCrossRefPubMed
24.
go back to reference Crago AM, Socci ND, DeCarolis P, O’Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S: Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012, 18 (5): 1334-1340.PubMedCentralCrossRefPubMed Crago AM, Socci ND, DeCarolis P, O’Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S: Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012, 18 (5): 1334-1340.PubMedCentralCrossRefPubMed
25.
go back to reference Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007, 18 (3): 263-270.CrossRefPubMed Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007, 18 (3): 263-270.CrossRefPubMed
26.
go back to reference Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004, 24 (1): 29-33.CrossRefPubMed Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004, 24 (1): 29-33.CrossRefPubMed
27.
go back to reference Cunningham BA, Moncur JT, Huntington JT, Kinlaw WB: “Spot 14” protein: a metabolic integrator in normal and neoplastic cells. Thyroid. 1998, 8 (9): 815-825.CrossRefPubMed Cunningham BA, Moncur JT, Huntington JT, Kinlaw WB: “Spot 14” protein: a metabolic integrator in normal and neoplastic cells. Thyroid. 1998, 8 (9): 815-825.CrossRefPubMed
28.
go back to reference Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT: Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology. 2006, 147 (9): 4048-4055.CrossRefPubMed Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT: Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology. 2006, 147 (9): 4048-4055.CrossRefPubMed
29.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha WS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1 (5): 555-567.PubMedCentralCrossRefPubMed Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha WS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1 (5): 555-567.PubMedCentralCrossRefPubMed
30.
go back to reference Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT: Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008, 105 (26): 9053-9058.PubMedCentralCrossRefPubMed Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT: Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008, 105 (26): 9053-9058.PubMedCentralCrossRefPubMed
31.
go back to reference Csiszar K: Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol. 2001, 70: 1-32.CrossRefPubMed Csiszar K: Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol. 2001, 70: 1-32.CrossRefPubMed
32.
go back to reference Erler JT, Giaccia AJ: Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006, 66 (21): 10238-10241.CrossRefPubMed Erler JT, Giaccia AJ: Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006, 66 (21): 10238-10241.CrossRefPubMed
33.
go back to reference Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J: Lysyl oxidase as a potential therapeutic target. Drug News Perspect. 2008, 21 (4): 218-224.CrossRefPubMed Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J: Lysyl oxidase as a potential therapeutic target. Drug News Perspect. 2008, 21 (4): 218-224.CrossRefPubMed
34.
go back to reference Ferrini FS, Rossi MA, Neto MM, Soares FA: Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein. Sao Paulo Med J. 2001, 119 (1): 4-6.CrossRefPubMed Ferrini FS, Rossi MA, Neto MM, Soares FA: Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein. Sao Paulo Med J. 2001, 119 (1): 4-6.CrossRefPubMed
35.
go back to reference Gamgee S: On the removal of scirrhous tumors of the breast. Br Med J. 1877, 844: 255-CrossRef Gamgee S: On the removal of scirrhous tumors of the breast. Br Med J. 1877, 844: 255-CrossRef
37.
go back to reference Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2 (2): E7-PubMedCentralCrossRefPubMed Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2 (2): E7-PubMedCentralCrossRefPubMed
38.
go back to reference Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315 (26): 1650-1659.CrossRefPubMed Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315 (26): 1650-1659.CrossRefPubMed
39.
go back to reference Elenbaas B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001, 264 (1): 169-184.CrossRefPubMed Elenbaas B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001, 264 (1): 169-184.CrossRefPubMed
40.
go back to reference Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002, 62 (18): 5351-5357.PubMed Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002, 62 (18): 5351-5357.PubMed
41.
go back to reference Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59 (19): 5002-5011.PubMed Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59 (19): 5002-5011.PubMed
42.
go back to reference West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M: Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005, 3 (6): e187-PubMedCentralCrossRefPubMed West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M: Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005, 3 (6): e187-PubMedCentralCrossRefPubMed
43.
go back to reference Baba Y, Iyama K, Ikeda K, Ishikawa S, Hayashi N, Miyanari N, Sado Y, Ninomiya Y, Baba H: The expression of type IV collagen alpha6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2008, 15 (2): 555-565.CrossRefPubMed Baba Y, Iyama K, Ikeda K, Ishikawa S, Hayashi N, Miyanari N, Sado Y, Ninomiya Y, Baba H: The expression of type IV collagen alpha6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2008, 15 (2): 555-565.CrossRefPubMed
44.
go back to reference Bauer R, Ratzinger S, Wales L, Bosserhoff A, Senner V, Grifka J, Grassel S: Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem. 2011, 27 (3–4): 217-226.CrossRefPubMed Bauer R, Ratzinger S, Wales L, Bosserhoff A, Senner V, Grifka J, Grassel S: Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem. 2011, 27 (3–4): 217-226.CrossRefPubMed
45.
go back to reference Moh MC, Shen S: The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhes Migr. 2009, 3 (4): 334-336.CrossRef Moh MC, Shen S: The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhes Migr. 2009, 3 (4): 334-336.CrossRef
46.
go back to reference Wu JM, Beck AH, Pate LL, Witten D, Zhu S, Montgomery KD, Allison KH, van de Rijn M, West RB: Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res. 2011, 17 (3): 437-446.PubMedCentralCrossRefPubMed Wu JM, Beck AH, Pate LL, Witten D, Zhu S, Montgomery KD, Allison KH, van de Rijn M, West RB: Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res. 2011, 17 (3): 437-446.PubMedCentralCrossRefPubMed
47.
go back to reference Vaghjiani RJ, Talma S, Murphy CL: Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells. Tissue Eng A. 2009, 15 (8): 2073-2083.CrossRef Vaghjiani RJ, Talma S, Murphy CL: Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells. Tissue Eng A. 2009, 15 (8): 2073-2083.CrossRef
48.
go back to reference Grunewald TG, Ranft A, Esposito I, da Silva-Buttkus P, Aichler M, Baumhoer D, Schaefer KL, Ottaviano L, Poremba C, Jundt G, Jurgens H, Dirksen U, Richter GH, Burdach S: High STEAP1 expression is associated with improved outcome of Ewing’s sarcoma patients. Ann Oncol. 2012, 23 (8): 2185-2190.CrossRefPubMed Grunewald TG, Ranft A, Esposito I, da Silva-Buttkus P, Aichler M, Baumhoer D, Schaefer KL, Ottaviano L, Poremba C, Jundt G, Jurgens H, Dirksen U, Richter GH, Burdach S: High STEAP1 expression is associated with improved outcome of Ewing’s sarcoma patients. Ann Oncol. 2012, 23 (8): 2185-2190.CrossRefPubMed
49.
go back to reference Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Muller-Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, Sickmann A, Prazeres da Costa O, Gorlach A, Cossarizza A, Butt E, Richter GH, Burdach S: STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 2012, 10 (1): 52-65.CrossRefPubMed Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Muller-Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, Sickmann A, Prazeres da Costa O, Gorlach A, Cossarizza A, Butt E, Richter GH, Burdach S: STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 2012, 10 (1): 52-65.CrossRefPubMed
50.
go back to reference Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B, Yen Y: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer. 2009, 8: 11-PubMedCentralCrossRefPubMed Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B, Yen Y: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer. 2009, 8: 11-PubMedCentralCrossRefPubMed
Metadata
Title
Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas
Authors
Keith M Skubitz
Amy PN Skubitz
Wayne W Xu
Xianghua Luo
Pauline Lagarde
Jean-Michel Coindre
Frédéric Chibon
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-176

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.